The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis (INESEP)

August 19, 2021 updated by: Central Hospital, Nancy, France

The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis - Longitudinal Observational Study - INESEP

Although the majority of the French population is covered by social security, the effects of social inequalities on health are still very visible and are even increasing in France and in Europe. Thus, according to INSEE, excess mortality is observed among the most disadvantaged populations. Similarly, the prevalence of certain chronic diseases in France and Europe, particularly cardiovascular diseases, is linked to social inequalities and excess morbidity can be observed in the most disadvantaged populations.

In addition to social inequalities, which refer to disparities in health levels according to social category, there are the effects of territorial inequalities. In France, there are geographical areas of excess mortality, which essentially correspond to areas far from urban centers. Similarly, there are major geographical differences in terms of medical supply and equipment, and the distance between patients and health centers is a direct obstacle to the use of the health care network.

The underlying explanations for social inequalities in health are multiple. While it is likely that difficulties in accessing and using care play a role, it is also possible that they are due to differences in exposure to certain environmental (e.g. pollution) or individual (e.g. smoking) risk factors. But it is also possible that the causal relationship is the opposite and that diseases create or reveal social inequalities.

For multiple sclerosis (MS) the impact of social and territorial inequalities is more debated. Indeed, with regard to the relationship between disease prevalence and social inequalities, a recent literature review found 21 separate studies on the subject, of which 13 failed to show a link between socioeconomic status and MS risk, 5 concluded that there was an increased risk of MS in advantaged populations and 3 concluded that there was an increased risk of MS in disadvantaged populations. There are plausible pathophysiological explanations for either direction of the relationship, but the question remains open.

To our knowledge, the link between MS prognosis and social inequalities has been little studied, as disadvantaged populations are more often exposed to the poor prognostic factor of smoking [6-8], the hypothesis of a negative prognostic role of social inequalities remains plausible. Similarly, the current consensus is that the diagnosis and treatment of MS should be as early as possible [9,10] in order to preserve brain capital. Easy access to a neurologist and MRI are therefore potentially prognostic factors for MS in relation to territorial inequalities. It should be noted that the link between social and geographical inequalities and a potential delay in treatment has not been demonstrated in France in the case of cancer, but it is possible that the importance of the means implemented in the fight against cancer erases these effects. In MS, a study showed a link between delay in starting a second disease-modifying therapy and socio-economic status.

While the causal link between MS and socio-professional status has not yet been demonstrated, the socio-economic impact of MS has been measured. In particular, it has been shown that having MS is associated with an increased risk of unemployment and/or early retirement.

The primary objective of our study is to determine whether delay in treatment, as a marker of difficulties in access to care in MS, is associated with social and territorial inequalities in MS. Secondary objectives will be to explore the link between MS prognosis and social and territorial inequalities.

Exposure to sunlight is a known protective factor and is consistent with the north-east-south-west gradient observed in France. The choice of centers associated with the research, spread over the French territory, will make it possible to monitor and measure this effect in the prognosis of MS.

As the available treatments have evolved considerably over the last ten years, and in order to avoid a period effect, the patients recruited in the study will have to have a date of onset of the disease after 1 January 2009.

Primary objective Determining the relationship between socio-economic inequalities and the time to start disease-modifying therapy in MS Secondary objective

  1. To determine the relationship between geographical inequalities and delay in starting disease-modifying therapy in MS
  2. To determine the relationship between socio-economic inequalities and time to walking disability (EDSS 4)
  3. To determine the relationship between geographical inequalities and time to walking disability (EDSS 4)
  4. To measure the impact of disability on socioeconomic status in MS patients

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Bordeaux, France, 33000
        • Recruiting
        • Service de Neurologie et Maladies inflammatoires du Système nerveux central
        • Contact:
        • Sub-Investigator:
          • Jean-Christophe OUALLET
        • Sub-Investigator:
          • Pauline BUISSONNIERE
        • Sub-Investigator:
          • Louis NADAL
      • Clermont-ferrand, France, 63000
      • Nancy, France, 54000
        • Recruiting
        • Service de neurologie
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Guillaume MATHEY
        • Sub-Investigator:
          • Sophie PITTION
        • Sub-Investigator:
          • Chloe PRUNIS
      • Rennes, France, 35000
      • Vandœuvre-les-Nancy, France, 54511
        • Active, not recruiting
        • CIC 1433 Épidémiologie CliniqueInserm, CHRU, Université de Lorraine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study population:

Patients with a confirmed diagnosis of MS whose clinical data are present in the EDMUS database.

Recruitment methods:

Inclusion will be done during the usual consultations of the patients in their care centers, corresponding to one of the 4 investigating centers. The study will be offered to all patients who meet the inclusion criteria

Description

Inclusion criteria

  • Be of legal age
  • Have a confirmed MS according to the McDonald criteria 2017
  • Have the date of onset of the disease recorded in EDMUS
  • Have a disease onset date after 1 January 2009

  • For patients receiving treatment for their MS*: have the date of first disease- modifying therapy entered in EDMUS

    • Patients not receiving treatment for their MS can be included if they meet the other criteria

Exclusion criteria

• Being deprived of liberty or under guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The endpoint will be the time from disease onset to treatment, and the co-variates of the multivariate model will be all socio-demographic and clinical characteristics at disease onset.
Time Frame: The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.
The endpoint will be the time from disease onset to treatment, and the co-variates of the multivariate model will be all socio-demographic and clinical
The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Delay before first treatment
Time Frame: The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.
Delay before first treatment
The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.
Time to reach an EDSS of more than 4
Time Frame: The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.
Time to reach an EDSS of more than 4
The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.
Difference in disposable income between the start of the illness and the point date.
Time Frame: The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.
Difference in disposable income between the start of the illness and the point date.
The total time for a subject to participate is approximately 25 minutes, while reading the newsletter, asking questions if necessary and completing a questionnaire.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Investigators

  • Principal Investigator: Marc DEBOUVERIE, PU-PH, Service de Neurologie CHRU de Nancy
  • Principal Investigator: Aurélie RUET, PU-PH, Service de Neurologie et Maladies inflammatoires du Système nerveux central
  • Principal Investigator: Gilles EDAN, PU-PH, PÔLE NEUROSCIENCES, CHU de Rennes
  • Principal Investigator: Pierre CLAVELOU, PU-PH, Service de Neurologie, CHU de Clermont-Ferrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2021

Primary Completion (Anticipated)

March 3, 2023

Study Completion (Anticipated)

June 30, 2023

Study Registration Dates

First Submitted

August 19, 2021

First Submitted That Met QC Criteria

August 19, 2021

First Posted (Actual)

August 23, 2021

Study Record Updates

Last Update Posted (Actual)

August 23, 2021

Last Update Submitted That Met QC Criteria

August 19, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019-A02739-48

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe